2024 Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Group Acute Leukemia Working Party (ALWP) 1st listed author Frédéric Baron Journal Am J Hematol.
2024 Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study Group Acute Leukemia Working Party (ALWP) Other society 1st listed author Dietger Niederwieser Journal Haematologica.
2024 Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Bone Marrow Transplant.
2024 Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Rama Al Hamed Journal Bone Marrow Transplant.
2024 Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Razan Mohty Journal Bone Marrow Transplant.
2024 Young (<35 years) haploidentical versus old (≥35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Bone Marrow Transplant.
2024 Impact of the type of tyrosine kinase inhibitor (imatinib or dasatinib) used before allo-HCT on outcome of patients with Philadelphia-positive acute lymphoblastic leukemia. A study on behalf of the Acute Leukemia Working Party of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Sebastian Giebel Journal Transplant Cell Ther.
2024 Tacrolimus versus cyclosporine a combined with post-transplantation cyclophosphamide for AML In first complete remission: a study from the acute leukemia working party (EBMT) Group Acute Leukemia Working Party (ALWP) 1st listed author Gesine Bug Journal Bone Marrow Transplant.
2024 Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Am J Hematol.
2024 Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working party Group Acute Leukemia Working Party (ALWP) 1st listed author Jean El Cheikh Journal Bone Marrow Transplant.
2024 Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patient Group Acute Leukemia Working Party (ALWP) 1st listed author Ann-Kristin Schmälter Journal Blood Cancer J.
2024 Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT Group Acute Leukemia Working Party (ALWP) Global Committee 1st listed author Yishan Ye Journal Blood Cancer J.